Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Invested Capital (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Invested Capital readings, the most recent being $35.5 million for Q4 2025.

  • On a quarterly basis, Invested Capital rose 187.6% to $35.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.5 million, a 187.6% increase, with the full-year FY2025 number at $35.5 million, up 187.6% from a year prior.
  • Invested Capital hit $35.5 million in Q4 2025 for Fennec Pharmaceuticals, up from $13.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $35.5 million in Q4 2025 to a low of $2.8 million in Q3 2022.
  • Median Invested Capital over the past 5 years was $18.0 million (2023), compared with a mean of $19.1 million.
  • Biggest five-year swings in Invested Capital: crashed 88.33% in 2022 and later soared 416.38% in 2023.
  • Fennec Pharmaceuticals' Invested Capital stood at $20.8 million in 2021, then increased by 7.99% to $22.4 million in 2022, then dropped by 18.07% to $18.4 million in 2023, then crashed by 32.89% to $12.3 million in 2024, then soared by 187.6% to $35.5 million in 2025.
  • The last three reported values for Invested Capital were $35.5 million (Q4 2025), $13.7 million (Q3 2025), and $10.7 million (Q2 2025) per Business Quant data.